Results 181 to 190 of about 51,036 (300)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Disproportionality analysis to investigate fatal adverse events with immune checkpoint inhibitors: Proceed with extreme caution. [PDF]

Proc Natl Acad Sci U S A
Revol B, Khouri C, Raschi E.
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Correction: Model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, 2004–2015

BMC Infectious Diseases
Elsa Negro-Calduch, Tom Cattaert, Thomas Verstraeten   +2 more
doaj   +1 more source

Pharmacovigilance in medical cannabis therapy among physicians in Poland: pharmacovigilance knowledge, ADR reporting practice and cannabis-related safety reporting. [PDF]

Front Public Health
Kopciuch D, Kapcińska A, Kus K, Russo E.   +3 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Cross-national disparities in drug interaction reporting and assessment between Switzerland and Austria: A retrospective, registry-based study using pharmacovigilance data. [PDF]

PLoS One
Rainer M, Martinez De la Torre A, Bellmann R, Burden AM, Weiler S.   +4 more
europepmc   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Comments on Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation [Response To Letter]. [PDF]

Drug Des Devel Ther
Tobaiqy M, Alqutub ST.
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source